Glucocorticoid induced osteoporosis: Increased awareness as a management strategy for prevention of this complication in patients with systemic autoimmune rheumatic disease

Simple item page
dc.contributor.authorBankole, Adegbengaen
dc.contributor.authorGreear, Emma L.en
dc.date.accessioned2023-09-01T13:41:20Zen
dc.date.available2023-09-01T13:41:20Zen
dc.date.issued2023-08en
dc.date.updated2023-09-01T12:05:29Zen
dc.description.abstractBackground: It has been estimated that about 1% of the US population is treated with long-term glucocorticoids. High doses of glucocorticoids particularly those used by rheumatologists and others for systemic autoimmune rheumatic disease result in bone loss, causing glucocorticoid-induced osteoporosis and an increase in the risk of fractures. The increased risk is related to both the daily dose and the cumulative dose of the glucocorticoids. Despite the availability of effective preventative and treatment options, glucocorticoid-induced osteoporosis is often not mitigated with the use of these preventive therapies. The risk of glucocorticoid-induced osteoporosis often also goes underrecognized, because it occurs in a different group of patients compared to age-related osteoporosis. As a result, glucocorticoid-induced osteoporosis is not always treated until after fractures may have occurred. Our objective is to determine if a structured health-care provider’s educational intervention with intermittent educational updates would lead to improvement in the identification, evaluation, and prevention of glucocorticoid-induced osteoporosisin those patients at the highest risk of glucocorticoid-induced osteoporosis. Methods: In this single-center, prospective study, patients over 40 years of age, receiving a total cumulative dose of glucocorticoids of >5 g or a single dose of >30 mg of prednisone or its equivalent was enrolled. All providers attended an academic Journal Club, where the current American College of Rheumatology guidelines regarding glucocorticoid-induced osteoporosiswas reviewed. All providers received monthly reminders during academic meetings within the department. Results: There was a statistically significant improvement between pre- and post-educational data, with increasing use of glucocorticoid-induced osteoporosis preventive measures, which was sustained over the 12-month duration of the study. Conclusion: This research shows the importance of provider education as a means of disseminating information and improving the quality of patient care.en
dc.description.versionPublished versionen
dc.format.mimetypeapplication/pdfen
dc.identifier.doihttps://doi.org/10.5152/eurjrheum.2023.22086en
dc.identifier.issn2147-9720en
dc.identifier.orcidBankole, Adegbenga [0000-0001-6464-5367]en
dc.identifier.urihttp://hdl.handle.net/10919/116183en
dc.language.isoenen
dc.publisherAVES Yayinciliken
dc.rightsCreative Commons Attribution-NonCommercial 4.0 Internationalen
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/en
dc.subjectOsteoporosisen
dc.titleGlucocorticoid induced osteoporosis: Increased awareness as a management strategy for prevention of this complication in patients with systemic autoimmune rheumatic diseaseen
dc.title.serialEuropean Journal of Rheumatologyen
dc.typeArticle - Refereeden
dc.type.dcmitypeTexten
dc.type.otherArticleen
pubs.organisational-group/Virginia Techen
pubs.organisational-group/Virginia Tech/VT Carilion School of Medicineen
pubs.organisational-group/Virginia Tech/VT Carilion School of Medicine/Internal Medicineen
pubs.organisational-group/Virginia Tech/VT Carilion School of Medicine/Internal Medicine/Rheumatologyen
pubs.organisational-group/Virginia Tech/VT Carilion School of Medicine/TEACH Membersen

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
EJR_20220086_nlm_new_indd(1).pdf
Size:
439.02 KB
Format:
Adobe Portable Document Format
Description:
Published version
Download

Collections

All Faculty Deposits
Scholarly Works, Virginia Tech Carilion School of Medicine (VTCSOM)